Pacira Pharmaceuticals, Inc. Stock News

Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing.

Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.

Viatris said on Thursday ‌it will buy Pacira Biosciences for $1.65 billion, adding the ​pain therapy maker's ​products to its portfolio.

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities Expected to Be Synergistic With Viatris' Fast-Acting Meloxicam Opportunity Deal Anticipate...

Caregivers say they need clearer pain management plans, earlier education, and practical support on non-opioid options before a loved one undergoes surgery BRISBANE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, and Caregiver Action Netw...

– Expands patient access to opioid-sparing pain control and advances 5x30 strategy –  BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic partnership with Molteni Farmaceutici to expand access to opioid-sp...

BRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 2, 2026 to five new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material in...

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on August 4, 2026 to five new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material induce...